DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Study to Determine the Phototoxity of Atralin (Tretinoin) Gel, 0.05%

Information source: Coria Laboratories, Ltd.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy

Intervention: Atralin (tretinoin) Gel, 0.05% (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Coria Laboratories, Ltd.

Official(s) and/or principal investigator(s):
Joseph Stanfiled, MS, Principal Investigator, Affiliation: Suncare Laboratories


To assess the potential of tretnoin gel 0. 05% to produce phototoxic reactions, measured as skin reactions 24 and 48 hours after UV radiation of drug on skin.

Clinical Details

Official title: Clinical Evaluation of the Phototoxic Potential of Atralin (Tretinoin) Gel, 0.05%

Study design: Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)

Primary outcome: UV induced skin sensitization


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Normal healthy volunteers

- 18 years of age or older

Exclusion Criteria:

- Less than 18 years of age

Locations and Contacts

Suncare Research Laboratories, Winston-Salem, North Carolina 27106, United States
Additional Information

Starting date: January 2008
Last updated: March 26, 2008

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017